Indian pharmaceutical major Zydus Lifesciences is reportedly evaluating a majority acquisition of US-listed biopharmaceutical firm Ardelyx Inc, in a transaction estimated at $2.2–2.5 billion, according to sources cited by Mint. While the development has not been officially confirmed by the company, the scale and nature of the deal signal a potentially decisive strategic inflection point for Zydus as it seeks to rebalance its portfolio away from commoditised generics toward innovative therapies.

Zydus has, over the last few years, steadily articulated its ambition to build a meaningful presence in specialty and innovative medicines, particularly in the US market. This strategy has gained urgency amid sustained pricing pressure in generics, regulatory tightening, and rising competition from global peers. Against this backdrop, the company has selectively pursued overseas acquisitions and partnerships to acquire capabilities, assets, and pipelines that would otherwise take years to build organically.

The reported Ardelyx transaction would be Zydus’s largest overseas acquisition to date and among the biggest outbound healthcare deals by an Indian drugmaker. Ardelyx is listed on Nasdaq and, as of January 20, carried a market capitalisation of about $1.7 billion. The company focuses on first-in-class small-molecule drugs addressing gastrointestinal and cardio-renal diseases—areas that align with Zydus’s stated interest in differentiated and chronic therapies.

According to the report, Zydus is exploring the purchase of a majority stake in Ardelyx, with the deal likely funded through a combination of internal accruals and a proposed ₹5,000-crore equity raise via a qualified institutional placement. If executed, this would represent a significant balance sheet commitment and a clear shift in capital allocation priorities toward innovation-led growth.

Ardelyx reported revenue of $378 million in calendar year 2025, up 18% year-on-year, suggesting that it is not an early-stage asset but a commercial-stage biotech with scaling potential. For Zydus, acquiring a controlling stake would provide immediate access to marketed products, a specialised R&D platform, and a stronger on-ground presence in the US specialty pharma ecosystem.

For Zydus, the reported move reflects a deliberate attempt to reduce earnings volatility linked to generics cycles and regulatory shocks. Innovative and specialty drugs typically offer longer product lifecycles, stronger pricing power, and higher entry barriers. A majority acquisition, as opposed to a minority investment or licensing deal, would also give Zydus greater strategic and operational control.

This approach is consistent with the company’s recent actions. Over the past year, Zydus acquired two biologics contract development and manufacturing facilities in the US from Agenus Inc. for $75 million upfront and completed a full acquisition of French medical device maker Amplitude Surgical for about €300 million. More recently, it entered the consumer wellness space overseas with the £239 million acquisition of UK-based Comfort Click.

There has been no official statement from Zydus confirming or denying the Ardelyx discussions. However, management commentary in recent quarters has repeatedly emphasised innovation as a core growth pillar. Zydus has also stepped up in-house R&D, reporting positive Phase 2(b)/3 trial results for saroglitazar magnesium in primary biliary cirrhosis patients in the US, with plans to file a new drug application with the US FDA in Q4 FY26. Additionally, it has secured approval to initiate Phase-II trials for a bivalent typhoid conjugate vaccine in India.

These developments suggest that any large acquisition would likely be positioned as complementary to internal innovation rather than a substitute for it.

From an Indian market perspective, a $2.5 billion overseas acquisition would inevitably raise questions around leverage, equity dilution, and return on capital employed. Zydus reported a strong Q2 FY26, with revenue rising 17% to ₹6,100 crore and net profit up 38% to ₹1,260 crore, providing some financial cushion. Still, funding part of the deal via a QIP could weigh on near-term stock sentiment.